Platelet-Derived Stromal Cell-Derived Factor-1 Is Required for the Transformation of Circulating Monocytes into Multipotential Cells

Noriyuki Seta¹, Yuka Okazaki¹, Hiroshi Miyazaki², Takashi Kato¹,³, Masataka Kuwana¹*

¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Innovative Drug Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Takasaki, Japan, ³Department of Biology, School of Education, Waseda University, Tokyo, Japan

Abstract

Background: We previously described a primitive cell population derived from human circulating CD14⁺ monocytes, named monocyte-derived multipotential cells (MOMCs), which are capable of differentiating into mesenchymal and endothelial lineages. To generate MOMCs in vitro, monocytes are required to bind to fibronectin and be exposed to soluble factor(s) derived from circulating CD14⁻ cells. The present study was conducted to identify factors that induce MOMC differentiation.

Methods: We cultured CD14⁺ monocytes on fibronectin in the presence or absence of platelets, CD14⁻ peripheral blood mononuclear cells, platelet-conditioned medium, or candidate MOMC differentiation factors. The transformation of monocytes into MOMCs was assessed by the presence of spindle-shaped adherent cells, CD34 expression, and the potential to differentiate in vitro into mesenchymal and endothelial lineages.

Results: The presence of platelets or platelet-conditioned medium was required to generate MOMCs from monocytes. A screening of candidate platelet-derived soluble factors identified stromal cell-derived factor (SDF)-1 as a requirement for generating MOMCs. Blocking an interaction between SDF-1 and its receptor CXCR4 inhibited MOMC generation, further confirming SDF-1’s critical role in this process. Finally, circulating MOMC precursors were found to reside in the CD14⁺CXCR4high cell population.

Conclusion: The interaction of SDF-1 with CXCR4 is essential for the transformation of circulating monocytes into MOMCs.

Introduction

Circulating CD14⁺ monocytes, which are heterogeneous in terms of surface markers, phagocytic capacity, and differentiation potential, are committed precursors in transit from the bone marrow to their ultimate site of activity [1]. Until recently, it was believed that monocytes could only differentiate into cells with phagocytic capacity such as macrophages, and dendritic cells [1–3]. However, there is growing evidence that circulating monocytes can differentiate into a variety of cell types in addition to phagocytes [4–8]. We previously identified a peripheral blood-derived cell population, termed monocyte-derived multipotential cells (MOMCs), that have a fibroblast-like morphology in culture and a unique phenotype positive for CD14, CD45, CD34, and type I collagen [9]. This population originates from circulating CD14⁺ monocytes, and contains primitive cells that can differentiate into cells with the typical phenotypes and functions of mesenchymal cells, neurons, and endothelium in vitro [8–12]. We recently showed that the intracranial delivery of MOMCs enhances functional recovery in a rat model for ischemic stroke [13]. On the other hand, MOMCs derived from patients with systemic sclerosis were functionally altered and deficient in their ability to differentiate into endothelial cells, either in vitro or in vivo [14]. These findings raised the possibility that circulating monocytes may contribute to tissue remodeling and regeneration through MOMC differentiation in physiologic and pathogenic states.

MOMCs are obtained with a 7-day culture of peripheral blood mononuclear cells (PBMCs) on fibronectin-coated plastic plates with 10% fetal bovine serum (FBS) as the only source of growth factors. Our previous research indicated that to generate MOMCs from circulating CD14⁺ monocytes in vitro, the monocytes are required to bind to fibronectin’s RGD domain via α5β1 integrin on the monocytes’ cell surface, and are required to be exposed to soluble factor(s) derived from the circulating CD14⁻ cell fraction [9,15]. However, the details of the molecular factors involved in this process remain unknown. In this study, we examined...
molecular factors involved in MOMC differentiation by focusing on soluble factor(s) derived from circulating CD14− cells.

Materials and Methods

Cell Preparations

PBMCs were isolated from heparinized venous blood from 10 healthy volunteers, aged 22–38, using Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) density-gradient centrifugation. In some experiments, 3.8% sodium citrate was used as an anticoagulant instead of heparin. Since the PBMC fraction was contaminated with a large number of platelets, we removed platelets from the PBMC fraction by MACS column separation using anti-CD61 monoclonal antibody (mAb)-coupled magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). The platelet-depleted PBMCs were then divided into CD14+ monocytes and CD14− PBMCs by MACS column separation using anti-CD14 mAb-coupled magnetic beads (Miltenyi Biotech). In some instances, the CD14+ monocytes were separated into two distinct populations based on high or low CXCR4 expression, by fluorescence-activated cell sorting. Specifically, CD14+ monocytes were incubated with PE-conjugated anti-CXCR4 mAb (BD Biosciences, San Diego, CA) or FITC-conjugated anti-CD11a mAb (Beckman-Coulter, Fullerton, CA) in combination with PC5-conjugated anti-CD14 mAb (Miltenyi Biotech), and were sorted with a FACS® Calibur system. The CD14+ cells with CXCR4 levels in the top and bottom 40% were used as CD14+CXCR4high and CD14+CXCR4low cells, respectively. CD14+CD11a+ cells were also isolated as a control for the sorting procedure.

Platelets were prepared from platelet-rich plasma by a filtration method described elsewhere [16], with modifications to avoid activating the platelets during the isolation procedure. Briefly, sterilized Sepharose CL-2B gel (GE Healthcare Biosciences, AB, Uppsala, Sweden) in phosphate buffer (0.1 M NaH2PO4-H2O, adjusted to pH 7 with NaOH) was washed and equilibrated with Tyrodes buffer (140 mM NaCl, 3 mM KCl, 1 mM MgCl2, 16.62 mM NaHCO3, pH 7.4, 5.5 mM glucose, and 10 mM HEPES) containing 0.5% bovine serum albumin (BSA) (Sigma, St. Luis, MO). After packing the Sepharose beads into a column, Tyrodes buffer containing 0.5% BSA was replaced with serum-free low-glucose Dulbecco’s modified Eagle’s medium (DMEM; Sigma). Platelet-rich plasma was prepared from peripheral blood by centrifugation (120 g for 10 minutes) and gently applied to the Sepharose column. Platelets were then collected in clouded drips before the plasma proteins exited the column.

The concentration of isolated cells was determined by counting the cells under an inverted microscope (IX81: Olympus, Tokyo, Japan). The protocol of this study was approved by the Ethics Committee of Keio University School of Medicine. All blood samples were obtained from subjects who had given written informed consent.

Preparation of Platelet-Conditioned Medium

Platelet-conditioned medium was prepared from autologous platelets by several methods. Platelets (4×10⁷/mL) in low-glucose DMEM containing 10% FBS (JRH Bioscience, Lenexa, KS) were cultured on plastic plates coated with fibronectin (Sigma) for 24 hours, and supernatants recovered by centrifugation (180 g for 10 minutes) were used directly as platelet-conditioned medium. Alternatively, platelets (2.5×10⁷/mL) in serum-free low-glucose DMEM were stimulated with one of the following platelet agonists: thrombin (1 U/mL; Mochida Pharmaceutical Co., Ltd., Tokyo, Japan), thrombin receptor activation peptide (SFLLRN; 50 μM), type I collagen (4 μg/mL), adenosine diphosphate (ADP; 400 μM), ristocetin (15 mg/mL), or epinephrine (50 μM) (Sigma) at 37°C for 15 minutes. Supernatants prepared by centrifugation and diluted 10 times with low-glucose DMEM containing 10% FBS were also used as platelet-conditioned medium. In some experiments, medium conditioned by thrombin-treated platelets was fractionated using an Ultrafree-MC Centrifugal Filter® (Millipore, Bedford, MA) with a 30-kDa nominal MW limit, resulting in media enriched in either proteins with a molecular weight (MW) greater than 30 kDa, or with proteins with an MW less than 30 kDa.

Cultures for Generating MOMCs

In the original method, MOMCs are generated by culturing PBMCs (2×10⁶/mL) for 7 days in low-glucose DMEM containing 10% FBS on fibronectin-coated plastic plates, without any additional growth factors [9]. To evaluate the cell populations and soluble factors required to transform circulating monocytes into MOMCs, CD14+ monocytes were cultured on fibronectin-coated plastic plates with or without autologous platelets (4×10⁷/mL), CD14− PBMCs (10⁴ cells/mL), or unfractionated or fractionated platelet-conditioned medium. In addition, CD14+ monocytes were cultured on fibronectin-coated plastic plates in low-glucose DMEM containing 10% FBS, in the presence or absence of serial concentrations of the following: interleukin (IL)-7, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF)-AA, PDGF-AB, IL-8, growth-related oncogene-α (GRO-α), epithelial cell-derived neutrophil-activating peptide 78 (ENA78), thymus and activation-regulated chemokine (TARC), stromal cell-derived factor (SDF)-1, platelet factor 4 (PF4), regulated upon activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein-1α (MIP-1α), monocyte chemoattractant protein-3 (MCP-3), or neutrophil-activating peptide 2 (NAP2). All of these cytokines, growth factors, and chemokines were purchased from R&D Systems (Minneapolis, MN, USA). In some instances, AMD 3100 (Sigma) was added to the MOMC generation culture at a final concentration of 0, 1, or 5 ng/mL.

In all cultures, medium containing floating cells was exchanged with fresh low-glucose DMEM with 10% FBS on day 3. The number and morphology of adherent cells was assessed under an inverted microscope on day 7. The number of total and spindle-shaped adherent cells in a 1 mm x 1 mm square was counted on 10 randomly selected fields, and the efficacy of adherent cell generation was expressed as the proportion (%) of the number of the cells of interest in the culture compared to those observed in a culture of CD14+ monocytes alone, in low-glucose DMEM containing 10% FBS during the entire culture period. In experiments using CD14+CXCR4high and CD14+CXCR4low cells, the results were expressed in comparison with CD14+CD11a+ cell cultures. The adherent cells were subsequently recovered with 0.25% trypsin and assayed for cell-surface phenotype and in vitro differentiation capacity.

Flow Cytometric Analysis

After staining with FITC-conjugated anti-CD34, FITC-conjugated anti-CD11a or PE-conjugated anti-CXCR4 mAb in combination with PC5-conjugated anti-CD14 mAb, cells were analyzed on a FACS® Calibur flow cytometer using CellQuest software (BD Biosciences). Viable cells were identified by gating based on forward and side scatter, and data were shown as logarithmic dot-plots or histograms.
Capacity for In Vitro Differentiation into Mesenchymal and Endothelial Lineages

Adherent cells obtained in various MOMC generation cultures were replated on fibronectin-coated chamber slides (BD Biosciences) in high-glucose DMEM containing 10% FBS, and were grown to semi-confluence. The cells were then cultured under conditions known to induce the differentiation of MOMCs into mesenchymal and endothelial lineages [9,12]. MOMCs cultured for 7 days under a mesenchymal-induction condition, as described previously [9], were analyzed for mesenchymal lineage-specific transcription factors, such as Cbfa1 for osteogenesis, Sox-9 for chondrogenesis, and peroxisome proliferation-activated receptor γ (PPARγ) for adipogenesis. For these analyses, the cells were incubated with goat anti-Cbfa1 or anti-Sox-9 polyclonal antibodies, or mouse anti-PPARγ mAb (Santa Cruz Biotechnology, Santa Cruz, CA), followed by AlexaFluor® 568 anti-goat or -mouse IgG antibodies (Molecular Probes, Eugene, OR). The cells were incubated with FITC-conjugated mouse anti-CD45 mAb (Dako Carpinteria, CA) and observed under a fluorescence microscope. Representative results of three independent experiments are shown. Bars: 50 μm.

doi:10.1371 journal.pone.0074246.g001

Statistical Analysis

All continuous values are shown as the mean ± standard deviation (SD). Comparisons between two groups were tested for statistical significance using the non-parametric Mann-Whitney U test.

Results

Identification of Circulating CD14⁺ cells Required For Generating MOMCs

We previously reported that to generate MOMCs, circulating CD14⁺ monocytes are required to bind to fibronectin and be exposed to peripheral blood CD14⁻ cells [9]. To identify the circulating CD14⁺ cells required for generating MOMCs, we first evaluated the potential role of platelets that contaminated the PBMC fraction isolated by Lymphoprep density-gradient centrifugation. We prepared CD14⁺ monocytes and CD14⁻ PBMCs from the PBMC fraction after removing the contaminating platelets by negative selection with anti-CD61 mAbs-coupled
magnetic beads. In addition, circulating platelets were isolated using a gel-filtration method to avoid activating the platelets during the separation procedure. Next, we set up MOMC generation cultures in which CD14+ monocytes were cultured alone, with platelets, or with platelet-depleted CD14+ PBMCs on fibronectin-coated plastic plates. More adherent cells appeared in the cultures with platelets or CD14+ PBMCs than in the culture with monocytes alone (Figure 1A and B). Adherent cells with a fibroblastic morphology typical of MOMCs predominated in the cultures with monocytes and platelets, but were rarely detected in those with monocytes alone or with monocytes and CD14+ PBMCs. Flow cytometric analysis showed that CD34 was expressed by the adherent CD14+ cells obtained from the cultures of monocytes and platelets, but not by those from cultures of monocytes alone or monocytes with CD14+ PBMCs (Figure 1C).

The adherent cells obtained in these cultures were placed in differentiation induction cultures to assess their ability to differentiate into mesenchymal and endothelial lineages. As shown in Figure 1D, the adherent cells obtained in cultures with monocytes and platelets showed nuclear expression of the lineage-specific transcription factors Chst1a, Sox-9, and PPARγ together with CD45, upon 7-day osteogenic, chondrogenic, and adipogenic induction treatment, respectively, and expression of the endothelial markers eNOS and Tie-2 upon endothelial induction treatment. In addition, functional osteoblasts, chondrocytes, and adipocytes were detected after 3 weeks of osteogenic, chondrogenic, and adipogenic induction treatment of adherent cells obtained in cultures with monocytes and platelets (data not shown). Adherent cells obtained in cultures of monocytes alone or monocytes plus CD14+ PBMCs lacked the capacity to differentiate into mesenchymal or endothelial lineages. Concordant findings were obtained from peripheral blood cells derived from three additional donors. Adherent cells obtained in cultures of monocytes and platelets on fibronectin had typical MOMC characteristics, including fibroblast-like morphology, CD34 expression, and the potential to differentiate toward mesenchymal and endothelial lineages [9], indicating that platelets are the primary circulating cell population contributing to the transformation of circulating CD14+ monocytes into MOMCs.

We then selected 16 candidate soluble factors required for MOMC generation, based on (i) being released from platelets upon activation and (ii) having a MW <30 kDa. These candidate factors included IL-7, EGF, bFGF, TGF-β, PDGF-AA, PDGF-AB, IL-8, GRO-α, ENA78, TARC, SDF-1, PF4, RANTES, MIP-1α, MCP-3, and NAP2. Serial concentrations of these candidate cytokines, growth factors, and chemokines were added to cultures of CD14+ monocytes on fibronectin derived from five donors, and the generation of MOMCs was evaluated (Figure 4). SDF-1 and RANTES were selected as potent factors that promoted the generation of spindle-like adherent cells in a dose-dependent manner (P<0.05 for both comparisons); bFGF, MIP-1α, and MCP-3 also promoted the appearance of adherent cells to some extent. Among the adherent cells generated in cultures with these candidate soluble factors, CD34 expression was detected in the monocytes cultured with SDF-1, but not in those cultured with RANTES, bFGF, MIP-1α, or MCP-3.

To confirm that SDF-1 was capable of inducing MOMCs, CD14+ monocytes from 10 independent donors were cultured on fibronectin in the presence of serial concentrations of SDF-1. SDF-1 increased the number of adherent cells with fibroblast-like morphology, in a dose-dependent manner (Figure 5A and B). Adherent cells generated in the presence of SDF-1 expressed CD34 (Figure 5C) and had multidifferentiation potential toward the osteogenic, chondrogenic, adipogenic, and endothelial lineages (Figure 5D). In addition, functional osteoblasts, chondrocytes, and adipocytes were successfully generated with 4-week mesenchymal induction treatment (data not shown). SDF-1 is a chemotactic factor for a variety of hematopoietic-lineage cells expressing the SDF-1 receptor CXCR4. To examine how blocking the interaction between SDF-1 and CXCR4 would affect MOMC generation, monocyte cultures on fibronectin with thrombin-treated platelet-conditioned medium were prepared in the presence of serial concentrations of AMD 3100, a CXCR4 antagonist. As shown in Figure 5E, AMD 3100 suppressed the generation of spindle-shaped adherent cells in a dose-dependent fashion.

These findings together indicate that the platelet-derived factor SDF-1 is required for generating MOMCs. However, in MOMC generation cultures consisting of CD14+ monocytes, fibronectin, and SDF-1, at least 5% FBS was required in the media to generate MOMCs (results not shown), indicating that other factor(s) in the serum were also required.
Effect of the Circulating CD14+ Monocytes’ CXCR4 Expression Level on the MOMC Differentiation Capacity

Nearly all the CD14+ monocytes in circulation express CXCR4 on their surface, but the expression level is highly variable (Figure 6A). The expression level of CXCR4 was almost the same between CD14+ monocytes derived from peripheral blood samples anticoagulated with heparin and sodium citrate. To evaluate how the level of CXCR4 expressed by circulating CD14+ monocytes affects their capacity to differentiate into MOMCs, we prepared CXCR4high and CXCR4low monocytes using fluorescent-activated cell sorting (Figure 6B). Flow cytometry revealed that these two cell populations expressed CXCR4 differently. The CD14+CXCR4high and CD14+CXCR4low cells were then cultured on fibronectin in the presence of thrombin-treated platelet-conditioned medium. Since nearly all the CD14+ monocytes in circulation express CD11a, CD14+CD11a+ cells prepared by fluorescent-activated cell sorting were used as a control. After 7 days of culture, spindle-shaped adherent cells appeared more
frequently in cultures of CD14\(^+\)\(\text{CXCR4}^\text{high}\) cells than in cultures of CD14\(^+\)\(\text{CXCR4}^\text{low}\) cells (Figure 6C and D), although adherent cells from these cultures expressed CD34 similarly (data not shown). Adherent cells obtained from the CD14\(^+\)\(\text{CXCR4}^\text{high}\) cell cultures expressed Chfα1, Sox-9, and PPAR\(c\) upon 7-day osteogenic, chondrogenic, and adipogenic induction cultures, respectively, and expressed cNOS and Tie-2 in endothelial induction cultures (Figure 6E). In contrast, these lineage-specific transcription factors and endothelial proteins were scarcely detectable in the adherent cells cultured from CD14\(^+\)\(\text{CXCR4}^\text{low}\) cells. MOMCs were also generated by culturing CD14\(^+\)\(\text{CXCR4}^\text{high}\) cells in the presence of SDF-1 instead of platelet-conditioned medium (data not shown). These results together indicate that MOMC precursors are abundant in the circulating CD14\(^+\)\(\text{CXCR4}^\text{high}\) cell fraction.

**Discussion**

Using a stepwise approach, this study successfully identified SDF-1 as a soluble factor required for transforming circulating CD14\(^+\) monocytes into MOMCs. First, we found that platelets played a critical role in generating MOMCs from circulating CD14\(^+\) monocytes. Subsequently, soluble factors with a MW, \(\leq 30\) kDa released from activated platelets were shown to contain MOMC differentiation factor(s). The screening of candidate platelet-derived soluble factors identified SDF-1 as a factor required for MOMC generation. The critical role of SDF-1 in this process was further confirmed by the finding that blocking the SDF-1-\(\text{CXCR4}\) interaction with AMD 3100 inhibited the MOMC generation. Finally, we found that circulating monocytic MOMC precursors were enriched in the CD14\(^+\)\(\text{CXCR4}^\text{high}\) cell population. Taken together with our previous findings [15], the transformation of circulating monocytes into MOMCs requires multiple signals through cell-surface \(\alpha\text{v}\beta_3\) integrin and \(\text{CXCR4}\). This information should be useful for investigating how circulating CD14\(^+\) monocytes acquire multidifferentiation potential, and for establishing an optimal culture condition for generating MOMCs for potential use in regenerative medicine.

SDF-1, also designated CXCL12, is a chemotactic factor for such varied cell types as stem cells, progenitor cells, and mature hematopoietic-lineage cells, such as monocytes. During embryogenesis, SDF-1 is critically involved in the development of hematopoietic, nerve, and endothelial tissues through its regulation of tissue progenitor cell migration, homing, and survival [17,18]. In adult life, the SDF-1-\(\text{CXCR4}\) axis is the key factor for stem- and immune-cell trafficking. For example, hematopoietic stem cells migrate from the bone marrow along the SDF-1 concentration gradient and contribute to tissue repair [19,20]. Moreover, Yamaguchi and colleagues found that SDF-1 released from activated platelets into the microcirculation is functionally involved in recruiting bone marrow-derived endothelial progenitor cells to vascular injury areas [21]. In contrast to its chemotactic activities, we have found that SDF-1 also modulates the cellular phenotype and differentiation potential of circulating CD14\(^+\) monocytes.

Although relatively little is known about CXCR4’s downstream signaling cascades, it has been shown that the binding of SDF-1 to CXCR4 in hematopoietic-lineage cells triggers G protein-mediated downstream signaling, including phosphoinositide-3 kinase, protein kinase A, protein kinase C, and mitogen-activated protein kinase, as well as G protein-independent tyrosine phosphorylation.
of Janus kinase (JAK) 2 and other members of the JAK signal transduction pathway [22]. These effector pathways regulate cell adhesion, locomotion, and chemotaxis, but how these signaling pathways elicit biological effects, such as proliferation and differentiation, is controversial. Given that $\alpha_5\beta_1$ integrin is also required for generating MOMC [15], interactions between CXCR4 and integrin signals are of potential interest [23]. In this regard, it has been reported that CXCR4 and integrin signals interact with each other and are crucial for retaining progenitor cells in the bone marrow by phosphorylating c-kit [24], a receptor tyrosine kinase that functions in such diverse biological functions as proliferation, survival, and differentiation [25]. To determine the mechanisms underlying the transdifferentiation of circulating monocytes into multipotential cells, we must examine the downstream signaling pathways of CXCR4 and $\alpha_5\beta_1$ integrin.

Figure 4. Screening of MOMC differentiation factor(s): 16 candidate cytokines, growth factors, and chemokines. CD14$^+$ monocytes were cultured on fibronectin with or without serial concentrations of various soluble factors released by activated platelets and having a MW <30 kDa. The generation of spindle-shaped adherent cells was expressed as a proportion (%) of those generated by culturing monocytes alone. Results show the mean and SD of five independent experiments. *$P<0.05$, compared with the culture without exogenous factors. IL, interleukin; EGF, epidermal growth factor; bFGF, basic fibroblast growth factor; TGFβ, transforming growth factor-β; PDGF, platelet-derived growth factor; GROα, growth-related oncogene-α; ENA78, epithelial cell-derived neutrophil-activating peptide 78; TARC, thymus and activation-regulated chemokine; SDF-1, stromal cell-derived factor-1; PF4, platelet factor 4; RANTES, regulated upon activation, normal T cell expressed and secreted; MIP-1α, macrophage inflammatory protein-1α; MCP-3, monocyte chemotactic protein-3; and NAP2, neutrophil-activating peptide 2.

doi:10.1371/journal.pone.0074246.g004
Activated platelets are known to release a variety of soluble factors stored in their granules, including cytokines, chemokines, and growth factors [16]. Interestingly, SDF-1 is produced mainly by mesenchymal cells and endothelium, not by platelets or other hematopoietic-lineage cells. Platelets hold substantial amounts of SDF-1 in their granules that exists in a complex with CXCR4, and

Figure 5. SDF-1 is required for generating MOMCs. CD14+ monocytes were cultured on fibronectin in the presence of serial concentrations of SDF-1. (A) The generation of spindle-shaped adherent cells, expressed as a proportion (%) of those generated from culturing monocytes alone. The results shown are the mean and SD of 10 independent experiments. (B) Morphology of adherent cells obtained in a culture with 100 ng/ml SDF-1. Bars: 200 μm. (C) Cell-surface CD34 expressed on adherent cells obtained in a culture with 100 ng/ml SDF-1, as analyzed by flow cytometry. Closed histograms indicate CD34 expression; open histograms represent staining with isotype-matched control mAb. (D) Multidifferentiation potential of adherent cells obtained in a culture with 100 ng/ml SDF-1. Cells treated for osteogenic, chondrogenic, adipogenic, and endothelial induction for 1 week were analyzed by immunohistochemical staining for Cbfa1, Sox-9, or PPARγ (red) in combination with CD45 (green), or for eNOS or Tie-2 (red) in combination with DAPI (blue), and were observed under a fluorescence microscope. Representative results of 3 independent experiments are shown. Bars: 50 μm. (E) AMD 3100, a CXCR4 antagonist, suppressed the generation of MOMCs. Circulating monocytes were cultured with platelet-conditioned medium on fibronectin in the presence of 0, 1, or 5 ng/ml AMD 3100. Results are expressed as a proportion (%) of the number of spindle-shaped adherent cells obtained in the culture of monocytes alone. *P<0.05, compared with culturing without AMD 3100.

doi:10.1371/journal.pone.0074246.g005
Figure 6. MOMC precursors are enriched in CD14+CXCR4^high cells. (A) Dot-plot analysis of expression of CD14 and CXCR4 in CD14+ monocytes derived from 2 independent donors. Peripheral blood samples were anticoagulated with heparin or sodium citrate immediately after blood sampling. (B) Dot-plot analysis of CXCR4 expression in CD14+ cells, gated by CXCR4^high and CXCR4^low cells for fluorescent-activated cell sorting. Cell-surface CXCR4 on CXCR4^high and CXCR4^low cells is shown as histograms. (C) Morphology of adherent cells obtained from CD14+CD11a+, CD14+CXCR4^high, or CD14+CXCR4^low cells cultured on fibronectin with platelet-conditioned medium. Bars: 200 μm. (D) The generation of spindle-shaped adherent cells, expressed as a proportion (%) of those generated by culturing CD14+CD11a+ cells. Results show the mean and SD of three independent experiments. (F) Multidifferentiation potential of cells obtained by culturing CD14+CXCR4^high and CD14+CXCR4^low cells. Cells treated for osteogenic, chondrogenic, adipogenic, and endothelial induction for 1 week were analyzed by immunohistochemical staining for Cbfa1, Sox-9, or PPARγ (red) in combination with CD45 (green), or for eNOS or Tie-2 (red) in combination with DAPI (blue), and were observed under a fluorescence microscope. Representative results of 3 independent experiments are shown. Bars: 50 μm.

doi:10.1371/journal.pone.0074246.g006
release SDF-1 when activated by various agonists [26]. Platelets have long been considered to function solely as chief effector cells in hemostasis. However, the growing evidence that soluble mediators released from activated platelets are involved not only in hemostasis, but also in inflammation, innate/adaptive immune responses, and tissue repair indicates that platelets are more multifunctional than previously thought [27].

Circulating monocytes are recruited to extra-vascular injury sites, where they are exposed to inflammatory cytokines, and differentiate into macrophages that take up debris, clean the tissue, and induce an acquired immune response. Since the differentiation of CD14+CXCR4high monocyte precursors into MOMCs requires that the monocytes bind to fibronectin and be exposed to SDF-1 released from activated platelets, circulating monocytes may encounter these signals at the injury site. In that case, these external signals would induce specific intracellular signals in the infiltrating monocyte precursors, leading to the acquisition of mesenchymal and endothelial differentiation potentials. The MOMCs would subsequently differentiate into tissue-specific cells in response to organ-specific environmental cues.

Fibrocytes, a population of circulating cells with fibroblast properties, are characterized by a distinctive phenotype positive for CD45, CD34, and type I collagen [28]. MOMCs and fibrocytes in cultures commonly have spindle-shaped morphology and express CD34 and type I collagen, but have several distinct characteristics. Specifically, MOMCs are generated from circulating monocytes without expression of CD34 [9]: this

**References**

1. Godon S (1995) The macrophage. Bioessays 17: 977–986.
2. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, et al. (2001) Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98: 2544–2554.
3. Serves-Delpech C, Arnould S, Jurdic P, Natal S, Grasset MF, et al. (2002) Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and megakaryocytes. BMC Immunol 3: 15–25.
4. Zhao Y, Glesne D, Huberman E (2003) A human peripheral blood monocyte-derived subset acts as plasmipotent stem cells. Proc Natl Acad Sci USA 100: 2426–2431.
5. Romagnani P, Annunziato F, Fioretti F, Lazzeri E, Mazzinghi B, et al. (2003) CD14(+)CD34+ cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 97: 314–322.
6. Bucala R, Spiegel LA, Cheney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71–81.
7. Seta N, Kuwana M (2007) Human circulating monocytes as multipotential progenitors. Keio J Med 56: 41–47.
8. Seta N, Kuwana M (2010) Derivation of multipotential progenitors from human circulating CD14(+) monocytes. Exp Hematol 38: 556–563.
9. Kuwana M, Okazaki Y, Kodama H, Isumi K, Yasuoka H, et al. (2003) Human circulating CD14(+) monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74: 833–845.
10. Kodama H, Inoue T, Watanabe R, Yasuoka H, Kawakami Y, et al. (2005) Cardiomyogenic potential of mesenchymal progenitors derived from human circulating CD14(+) monocytes. Stem Cell Dev 14: 676–686.
11. Kodama H, Inoue T, Watanabe R, Yasuoka H, Kawakami Y, et al. (2006) Neurogenic potential of progenitors derived from human circulating CD14(+) monocytes. Immunol Cell Biol 84: 209–217.
12. Kuwana M, Okazaki Y, Kodama H, Satoh T, Kawanami Y, et al. (2006) Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 24: 2733–2743.
13. Hattori H, Suzuki S, Okazaki Y, Suzuki N, Kuwana M (2012) Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats. J Neurosci Res 90: 479–488.
14. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takakura N, et al. (2010) Enhanced angiogenic potency of monocyte endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheum 62: 3929–3936.
15. Seta N, Okazaki Y, Isumi K, Miyazaki H, Kato T, et al. (2012) Fibronecetin binding is required for acquisition of mesenchymal/endothelial differentiation potential in human circulating monocytes. Clin Dev Immunol 2012: 820827.
16. Walkowiak B, Kralicz I, Michalce L, Majewksa E, Koziołekiewicz W, et al. (2000) Comparison of platelet aggregability and P-selectin surface expression on platelets isolated by different methods. Thromb Res 99: 495–502.
17. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382: 635–638.
18. Zou YR, Kottmann AH, Kuroda M, Tanishich I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 591–599.
19. Massberg S, Konrad I, Schurzinger K, Lorenz M, Schneider S, et al. (2006) Platelet secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 203: 1221–1233.
20. Kucia M, Ratajczak J, Reca R, Janowska-Wieczorek A, Ratajczak MZ (2004) Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. Blood Cells Mol Dis 32: 52–57.
21. Hattori K, Hiessig B, Tashiro K, Honjo T, Tateo M, et al. (2001) Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97: 3354–3360.
22. Sharma M, Afrin F, Satija N, Tripaptha GP, Gangenahalli GU (2011) Stromal-derived factor-1/CXCR4 signaling: indispensible role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev 20: 933–946.
23. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, et al. (2000) The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95: 3289–3296.
24. Cheng M, Qin G (2012) Progenitor cell mobilization and recruitment: SDF-1, CXCR4, +,-/integrin, and -k. Curr Top Mol Biol Sci 111: 243–264.
25. Edging CE, Hallberg B (2007) c-KIT-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 39: 1995–1998.
26. Vieira-de-Azevedo A, Campbell BA, Weyrich AS, Zimmerman GA (2011) Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immmunopathol 34: 5–30.
27. Weyrich AS, Zimmerman GA (2004) Platelets: signaling cells in the immune continuum. Trends Immunol 25: 489–495.
28. Bucala R, Spiegel LA, Cheney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71–81.